Sweeneys to make room for new leadership at Dorland

Share this article:
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
Harry and Rita Sweeney, the couple who founded medical communications firm Dorland Global 35 years ago, will leave their executive positions as of January 1st, 2008, the agency announced yesterday. Assuming the role of CEO and president will be Rich Minoff, a five-year veteran who helped orchestrate the $20.7-million sale of Dorland to Huntsworth PLC earlier this year.
The 125-person agency maintains two business units, advertising and PR. Clients include Johnson & Johnson, Roche and Boston Scientific.
“Harry and I are confident that [Minoff] will not only continue to service our clients and employees in the manner that Dorland Global is known for, but will also take the agency in a new direction with the Huntsworth organization,” said Rita Sweeney, who had served as president, chief operating officer. The COO position will be eliminated. Her husband is stepping down as CEO.
Minoff joined the agency in 2002 as president of Dorland Global Health Communications, a branding and marketing division which has grown 47% per year under his watch. In addition, he has 14 years of senior managerial experience at various agencies, along with 12 years on the client side working for GlaxoSmithKline and Wyeth.
Thanks to the March purchase, Dorland Global's two main business units, Dorland Global Health Communications and Dorland Global Public Relations, now serve as the US affiliate of the UK-based Huntsworth health division.
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.